ARCHIVES

NIH to Review Intramural Program: NCI’s Intramural Spending is 17 Percent, Higher than 11.1 Percent NIH-Wide Level

This article is from The Cancer Letter archive.

Vol. 40 No. 10 | March 7, 2014

Download PDF Visit The Full Archive

Related Articles

Phase II Study Cohort Fails To Overcome Erlotinib Resistance

April 26, 2013

Study Finds Short Term Tests Predict Carcinogenicity

April 25, 1980

Program Announcement Completes NCI switch To Control Research

April 16, 1982

In Brief: Lasker Awards; Blobel, Metcalf, Wexler, Rogers; Borch Named Center Director

October 1, 1993

NCI, FDA Make Progress On Some Issues, Bu Differences Remain On Endpoints

November 10, 1989

FDA Approves Bexxar For Treatment Of Non-Hodgkin’s Lymphoma.

July 4, 2003